Role of genetic variation in the human sodium–glucose cotransporter 2 gene (SGLT2) in glucose homeostasis

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther.85(5),513–519 (2009).▪ Discovered that treatment with the SGLT2 inhibitor, dapagliflozin, results in a significant reduction of fasting plasma glucose in patients with Type 2 diabetes.
  Medline CASGoogle Scholar
• 2  Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with Type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet375(9733),2223–2233 (2010).▪ The effect of the SGLT2 inhibitor, dapagliflozin, was examined in patients with Type 2 diabetes and inadequate glycemic control with metformin. After 24 weeks the patients had a significant reduction in their mean HbA1c.
  Medline CASGoogle Scholar
• 3  Moe OW, Berry CA, Rector FC Jr. Renal transport of glucose, amino acids, sodium, chloride and water. In: Brenner and Rector’s the Kidney (Volume 5). Brenner BM (Ed.). WB Saunders, PA, USA, 375–415 (1993).
  Google Scholar
• 4  Deetjen P, von Baeyer H, Drexel H. Renal glucose transport. In: Seldin and Giebisch´s the Kidney (Volume 2). Seldin DW, Giebisch G (Eds). Raven Press, NY, USA, 2873–2888 (1992).
  Google Scholar
• 5  Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA. Cloning of a human kidney cDNA with similarity to the sodium–glucose cotransporter. Am. J. Physiol.263(3 Pt 2),F459–F465 (1992).
  Medline CASGoogle Scholar
• 6  You GF, Lee WS, Barros EJG et al. Molecular characteristics of Na⁺-coupled glucose transporters in adult and embryonic rat-kidney. J. Biol. Chem.270(49),29365–29371 (1995).
  Medline CASGoogle Scholar
• 7  Kanai Y, Lee WS, You GF, Brown D, Hediger MA. The human kidney low affinity Na⁺/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J. Clin. Invest.93(1),397–404 (1994).
  Medline CASGoogle Scholar
• 8  van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum. Genet.111(6),544–547 (2002).
  Medline CASGoogle Scholar
• 9  Calado J, Soto K, Clemente C, Correia P, Rueff J. Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum. Genet.114(3),314–316 (2004).
  MedlineGoogle Scholar
• 10  Katsuno K, Fujimori Y, Takemura Y et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther.320(1),323–330 (2007).▪ The SGLT2 inhibitor, sergliflozin, increased urinary glucose excretion in mice, rats and dogs in a dose-dependent manner and reduced plasma glucose levels without stimulating insulin secretion in diabetic rats.
  Medline CASGoogle Scholar
• 11  Fujimori Y, Katsuno K, Ojima K et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur. J. Pharmacol.609(1–3),148–154 (2009).
  Medline CASGoogle Scholar
• 12  Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes57(6),1723–1729 (2008).▪▪ The SGLT2 inhibitor, dapagliflozin, induced renal glucose excretion in normal and diabetic rats and reduced hyperglycemia in diabetic rats. The data suggest that dapagliflozin has a greater effect in the kidney of diabetic rats.
  Medline CASGoogle Scholar
• 13  Macdonald FR, Peel JE, Jones HB et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes. Metab.12(11),1004–1012 (2010).▪ In obese diabetic rats, the SGLT2 inhibitor, dapagliflozin, reduced hyperglycemia, improved the insulin sensitivity and pancreatic β-cell function.
  Medline CASGoogle Scholar
• 14  Jurczak MJ, Lee HY, Birkenfeld AL et al.SGLT2 deletion improves glucose homeostasis and preserves pancreatic β-cell function. Diabetes60(3),890–898 (2011).
  Medline CASGoogle Scholar
• 15  Wilding JPH, Norwood P, T’joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with Type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care32(9),1656–1662 (2009).
  Medline CASGoogle Scholar
• 16  Tönjes A, Koriath M, Schleinitz D et al. Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs. Hum. Mol. Genet.18(23),4662–4668 (2009).
  MedlineGoogle Scholar
• 17  Tönjes A, Zeggini E, Kovacs P et al. Association of FTO variants with BMI and fat mass in the self-contained population of Sorbs in Germany. Eur. J. Hum. Genet.18(1),104–110 (2010).
  MedlineGoogle Scholar
• 18  World Health Organisation Expert Committee. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, part 1: diagnosis and classification of diabetes mellitus. World Health Organisation, Geneva, Switzerland, 1–59 (1999).
  Google Scholar
• 19  Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma-glucose and insulin concentrations in man. Diabetologia28(7),412–419 (1985).
  Medline CASGoogle Scholar
• 20  Wolever TM, Jenkins DJ. The use of the glycemic index in predicting the blood glucose response to mixed meals. Am. J. Clin. Nutr.43(1),167–172 (1986).
  Medline CASGoogle Scholar
• 21  Gaudermann WJ. Sample size requirements for association studies of gene–gene interaction. Am. J. Epidemiol.155(5),478–484 (2002).
  MedlineGoogle Scholar
• 22  Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract.62(8),1279–1284 (2008).
  Medline CASGoogle Scholar
• 23  Santer R, Kinner M, Lassen CL et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J. Am. Soc. Nephrol.14(11),2873–2882 (2003).
  Medline CASGoogle Scholar
• 24  List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium–glucose cotransport inhibition with dapagliflozin in Type 2 diabetes. Diabetes Care32(4),650–657 (2009).▪ Investigated the impact of the SGLT2 inhibitor dapagliflozin in Type 2 diabetes patients. Dapagliflozin lowers the HbA1c and affects weight loss.
  Medline CASGoogle Scholar
• 25  Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes. Metab.12(6),510–516 (2010).
  Medline CASGoogle Scholar
• 26  Feng Y, Mao G, Ren X et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients. Diabetes Care31(10),1939–1944 (2008).
  Medline CASGoogle Scholar
• 101  International HapMap Project www.hapmap.org
  Google Scholar